40. Chin Clin Oncol. 2018 Jun;7(3):26. doi: 10.21037/cco.2018.06.01.Advances in chemotherapy for HER2-negative metastatic breast cancer.Mukai H(1), Ito M(2).Author information: (1)Department of Breast and Medical Oncology, National Cancer Center HospitalEast, Chiba, Japan. hrmukai@east.ncc.go.jp.(2)Department of Breast and Medical Oncology, National Cancer Center HospitalEast, Chiba, Japan.Metastatic breast cancer cannot be curable, but significant improvement inoverall survival has been observed with the appearance of new agents. The purposeof treatment is to prolong survival and to improve quality of life by reducingcancer-related symptoms. To achieve these goals, individualized approach isrequired. Chemotherapy is used for patients with hormone receptor negative breastcancer or hormone receptor positive patients who have cancer-related symptoms.The choice of regimen (single-agent or a combination), selection of a specifictherapy and the duration of treatment depend on multiple factors, including thetumor burden, general health status, prior treatments and toxicities, and patientpreferences.DOI: 10.21037/cco.2018.06.01 PMID: 30056728 